- Home
- CXDO vs VTYX Comparison
CXDO vs VTYX Comparison
Compare CXDO & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CXDO
- VTYX
- Stock Information
- Founded
- CXDO 1995
- VTYX 2018
- Country
- CXDO United States
- VTYX United States
- Employees
- CXDO N/A
- VTYX N/A
- Industry
- CXDO Telecommunications Equipment
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- CXDO Telecommunications
- VTYX Health Care
- Exchange
- CXDO Nasdaq
- VTYX Nasdaq
- Market Cap
- CXDO 152.4M
- VTYX 154.9M
- IPO Year
- CXDO 1998
- VTYX 2021
- Fundamental
- Price
- CXDO $5.89
- VTYX $3.18
- Analyst Decision
- CXDO Strong Buy
- VTYX Buy
- Analyst Count
- CXDO 3
- VTYX 4
- Target Price
- CXDO $8.50
- VTYX $11.33
- AVG Volume (30 Days)
- CXDO 248.1K
- VTYX 1.7M
- Earning Date
- CXDO 08-05-2025
- VTYX 08-07-2025
- Dividend Yield
- CXDO N/A
- VTYX N/A
- EPS Growth
- CXDO 51.44
- VTYX N/A
- EPS
- CXDO 0.09
- VTYX N/A
- Revenue
- CXDO $62,609,000.00
- VTYX N/A
- Revenue This Year
- CXDO $13.10
- VTYX N/A
- Revenue Next Year
- CXDO $10.97
- VTYX N/A
- P/E Ratio
- CXDO $66.33
- VTYX N/A
- Revenue Growth
- CXDO 13.85
- VTYX N/A
- 52 Week Low
- CXDO $3.62
- VTYX $0.78
- 52 Week High
- CXDO $7.34
- VTYX $3.39
- Technical
- Relative Strength Index (RSI)
- CXDO 52.75
- VTYX 66.17
- Support Level
- CXDO $5.55
- VTYX $2.88
- Resistance Level
- CXDO $5.98
- VTYX $3.30
- Average True Range (ATR)
- CXDO 0.21
- VTYX 0.22
- MACD
- CXDO -0.03
- VTYX 0.03
- Stochastic Oscillator
- CXDO 39.39
- VTYX 87.02
About CXDO Crexendo Inc.
Crexendo Inc is a provider of cloud communications, UCaaS, call centers, collaboration services, and other cloud business services. The company operates through two segments: Cloud telecommunications and Software Solutions. Its cloud telecommunications segment offers hardware, software, and unified communication solutions for businesses using IP or cloud technology over any high-speed Internet connection. The Software Solutions segment is involved in revenue generation from software licenses, software maintenance support, and professional services. It generates subscription and maintenance support revenue from customer support and other supportive services. The company offers warranties on its products. It derives a majority of its revenue from the Cloud telecommunications segment.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.